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1. Introduction 
Cardiomyopathy is cardiac condition in which the normal muscular function of the 
myocardium has been altered by a variety of etiologies. Atherosclerotic coronary artery 
disease is the most common cause of cardiomyopathy in North America and Europe. 
Idiopathic cardiomyopathy is the second most common cause, although this may partially 
include undiagnosed etiologies such as viral infection, drug toxicity, and genetic factors. 
Other causes include endocrine diseases, collagen vascular diseases, metabolic disorders 
(hemochromatosis, amyloidosis, glycogen storage disease), neuromuscular disorders, and 
granulomatous diseases (sarcoidosis). 
The cardiac malfunctions are variable, namely left ventricular (LV) systolic dysfunction, LV 
diastolic dysfunction, or both in accordance with etiologies and morphological findings 
(cardiac hypertrophy or dilatation). For example, hypertrophic cardiomyopathy initially has 
LV diastolic dysfunction, while amyloidosis that shows similar morphological change has 
LV systolic dysfunction. Ischemic or idiopathic cardiomyopathy with ventricular dilatation 
is represented by systolic dysfunction. Cardiac malfunctions are also altered on disease 
course. Initially, patients with cardiomyopathy may have asymptomatic LV systolic or 
diastolic dysfunction alone. However, adverse disease processes finally lead to both 
dysfunctions.  
Imbalance between cardiac malfunctions and compensatory mechanisms worsens an 
outcome of cardiomyopathy. When abnormal LV filling pressure and volume is unable to be 
compensated by hemodynamic alterations such as the increases in heart rate and peripheral 
vascular tone by the accelerated vasoconstrictors including norepinephrine (NE), 
endothelin-1 (ET-1), and the renin-angiotensin-aldosterone (RAA), this imbalance 
precipitates decompensated heart failure (HF).  
Early and simply identifying the decompensatory process is important therapeutic 
strategy in cardiomyopathy. Clinical utility of B-type natriuretic peptide (BNP) 
sensitively produced and secreted from heart in response to LV overload has been 
extended rapidly in patients with HF. At first, BNP emerged as a diagnostic marker for 
decompensated HF. Furthermore, BNP has been proved to predict a subsequent outcome 
in patients with HF. Recently, the efficiency of BNP-guided therapy in patients with HF 
has been demonstrated. In this chapter, we discuss about clinical utility of BNP 
assessments in patients with cardiomyopathy.  
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2. B-type natriuretic peptide (BNP) 
 BNP is predominantly secreted from the overloaded LV as a 76 aminoacid N-terminal 
fragment and a 32 aminoacid active hormone, and synthesis and release of BNP are 
adversely and rapidly accelerated in conjunction with the degree of LV wall stretch (1-2). In 
addition to this primary regulation, BNP synthesis can be also upregulated by tachycardia, 
glucocorticoids, thyroid hormones, vasoactive peptides such as ET-1, angiotensin II, and 
NE, and inflammatory cytokines. On the other hand, BNP is clearance via the binding to a 
natriuretic peptide receptor (NPR)-C of three NPRs (NPR-A, -B, -C). BNP is also inactivated 
by neutral endopeptidase, a zinc metallopeptidase which is expressed on the surface of 
endothelial cells, smooth-muscle cells, cardiac myocytes, renal epithelium, and fibroblasts.  
BNP is included into compensatory mechanisms against HF. BNP promotes glomerular 
filtration and inhibits sodium reabsorption, resulting in natriuresis and diuresis. It reduces 
blood pressure through the relaxation of vascular smooth muscle and inhibits activations of 
not only central and peripheral sympathetic nerve systems but also cardiac sympathetic 
nervous system (3). Furthermore, it also inhibits the RAA system (4).  
2.1 BNP as a diagnostic marker  
2.1.1 BNP in heart failure 
Plasma BNP levels have proven utility in the diagnostic evaluation of decompensated HF in 
patients with acute dyspnea (5-6). Particularly, BNP at a cutoff of 100 pg/ml could diagnose 
HF better than not only all other clinical parameters but also the clinical judgement by the 
emergency room physicians. However, BNP also has the diagostic limitation for HF. BNP is 
less accurate in detection of asymptomatic LV dysfunction than clinical parameters, because 
BNP has a close correlation with New York Heart Association (NYHA) functional class and 
patients with mild LV dysfunction often show normal range of BNP levels.  
2.1.2 BNP in cardiomyopathy 
BNP levels are raised in dilated, hypertrophic, and restrictive cardiomyopathies. Its 
increases seem to be different in accordance with cardiac malfunctions. BNP levels are 
generally higher in patients with systolic dysfunction than in those with isolated 
diastolic dysfunction, and highest in those with both dysfunctions (7). Furthermore, 
among patients with preserved LV systolic function, BNP correlates with the severity of 
diastolic dysfunction. BNP levels are raised in patients with impaired relaxation and 
especially highest in those with a restrictive filling pattern (8). BNP measurements may 
facilitate understanding the type and severity of cardiac malfunction on 
cardiomyopathy.  
On the other hand, BNP measurement may be unavailable for distinguishing 
cardiomyopathies. Hypertrophic cardiomyopathy often shows extremely high levels of 
BNP, similarly to dilated cardiomyopathy (9). In addition, restrictive cardiomyopathy 
with systolic dysfunction also shows higher levels of BNP than that with diastolic 
dysfunction alone (8). However, several reports have demonstrated that BNP is able to 
distinguish constrictive pericarditis and restrictive cardiomyopathy, although these 
diseases overlap signs and symptoms of congestion (10). The level of BNP is elevated in 
patients with restriction, while level is nearly normal in those with constriction. The 
absence of cardiac stretch by constricting pericardium is thought to lead to lower BNP 
release. 
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2.2 BNP as a prognostic marker  
Prognostic values of BNP have been identified in various heart diseases such as HF, 
cardiovascular diseases, and cardiomyopathy. 
2.2.1 Heart failure 
In patients with HF, higher levels of BNP have been implicated in increased risk of 
cardiovascular or all-cause mortality and readmission for decompensated HF. Furthermore, 
the cutoff points on the risk assessment curve are altered on time course after 
decompensated HF. In admitted patients for decompensated HF, the cutoff point of 800 
pg/ml was associated with the increased risk of in-hospital mortality as shown by the 
ADHERE (Acute Decompensated Heart Failure National Registry) data (11). After the 
treatment, the predischarge cutoff point for the risk of readmission and mortality falls to 
about 500 pg/ml (12). The cutoff point further declined to abut 200 pg/ml in clinically stable 
outpatients after decompensated HF (13). These obsevations suggested that the therapeutic 
strategies for HF including a safe hospital discharge and the prevention of readmission or 
cardiac event may be guided by BNP measurement.  
2.2.2 Cardiovascular diseases 
In disorders other than HF, BNP also has prognostic value. BNP level is able to identify 
patients at the high risk group of adverse cardiac remodelling from patients with post-
myocardial infarction, independent of age, history of HF, and LV ejection fraction (LVEF) 
(14). Even in patients with unstable angina alone, increased levels of BNP were associated 
with an increased risk of death (15). In right ventricular dysfunction resulting from 
pulmonary hypertension, BNP also provides similar prognostic information. These 
observations have extended the potential role of BNP measurement to risk stratification of 
cardiovascular events in patients with and without HF.  
2.2.3 Cardiac inflammatory diseases; acute myocarditis 
Acute myocarditis is able to be mainly divided into two disease conditions on a basis of 
clinicopathologic profiles, namely fulminant and non-fulminant myocarditis (16-17). Briefly, 
fulminant myocarditis is represented by the distinct onset of cardiac symptoms within 2 weeks 
following flu-like symptoms accompanied by histologically proven active myocarditis 
according to Dallas criteria and severe circulatory failure requiring high-dose intravenous 
catecholamines use (>5.0 γ) or mechanical circulatory assist devise, while non-fulminant 
myocarditis is by the indistinct onset of cardiac symptoms without those. Furthermore, these 
outcomes are distinguished by each unique clinical course (17). Non-fulminant myocarditis 
has been implicated in poorer long-term outcome than fulminant cases. A few patients with 
fulminant myocarditis lapsed into mortality from severely deteriorated circulatory collapse 
refractory to mechanical circulatory assist use or mechanical complications from its long-term 
use, including bleeding, infections, sepsis, and multiple organ failure. However, more than 
80% of fulminant cases recover completely to an uncomplicated status, with cessation of 
myocardial inflammation and a generally favorable outcome, provided they are able to 
overcome poor cardiac condition successfully during acute phase (18). On the other hand, non-
fulminant myocarditis without severe circulatory failure is likely to develop to chronic HF 
derived from dilated cardiomyopathy at chronic phase (16-17). Therefore, simple biomarkers 
to predict a requirement of mechanical assist devise use, outcome following its use, or the 
development to cardiomyopathy in patients with acute myocarditis have been sought. 
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Previously, we related various variables to short-term outcome in patients with fulminant 
myocarditis (19). In-hospital mortality was extremely higher in patients with fulminant 
myocarditis than in non-fulminant cases. Especially, extremely increased levels of 
interleukin-10, a major anti-inflammatory cytokine in serum on admission were associated 
with short-term outcome including mechanical assist use and in-hospital mortality in 
patients with acute myocarditis (Figure 1), which might be explained by its inhibitory effect 
on viral elimination from host. A major pathogenic factor of acute myocarditis and 
subsequent cardiomyopathy is viral infection, especially coxsackievirus B3 (Table 1).  
 
  Patient positive (%) 
Virus Type Myocarditis 
Dilated 
cardiomyopathy 
Picornavirus Coxackie A, B 5-50% 5-15% 
 Echovirus ? ? 
 Hepatitis A ? ? 
 Hepatitis C 0-15% 0-10% 
Orthomyxovirus Influenza A, B ? ? 
Paramyxovirus RSV, Mumpus ? <1% 
Rubivirus/Toga 
virus 
Rubella virus ? <1% 
Rhabdo virus Rabies virus ? ? 
Arbovirus/Tahyna Dengue, yellow ? ? 
 fever virus   
Retrovirus/Lenti HIV Variable ? 
Herpes virus Varicella-zoster 1-2% 1-2% 
 Cytomegalovirus 1-15% 1-10% 
 Epstein-Barr virus 1-3% 1-3% 
 
Human herpes virus 
6 
0-5% 0-5% 
 herpes simplex virus 0-3% ? 
Mastadenovirus Adenovirus 5-20% 10-12% 
Parvovirus Parvo B 19 virus 10-30% 10-25% 
Table 1. Virus-induced myocarditis or cardiomyopathy 
Hoffmann et al also reported that IL-10 expression in human peripheral monocytes was 
strongly and persistently induced by coxsackievirus B3 infection in spite of only slight 
production of other pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6 (20). It has been 
reported that the inhibition of natural killer (NK) cells results in increased virus titers in the 
heart through delayed virus clearance (21). IL-10 inhibits the production of IFN-γ in NK cells, 
which has been demonstrated in association with susceptibility to Trypanosoma cruzi-induced 
myocarditis (22-23). In addition, it has been shown that IL-10 is transcribed in the myocardium 
parallel with viral replication in the acute and chronic stages of experimental Coxsackievirus 
B3 viral myocarditis (24-25). These findings imply that an extreme elevation of serum levels of 
IL-10, rather than TNF-α, on admission may reflect subsequent myocardial inflammation, 
which leads to the future deterioration of the disease, through delayed clearance of the virus.  
On the other hand, high levels of IL-10 may reflect a favorable long-term outcome in patients 
with acute myocarditis. Studies using experimental models have demonstrated a protective 
role of IL-10 in the development of acute myocarditis (26-27). This mechanism was explained 
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by its suppressive effect against excessive and persistent immune response to viral infection or 
a subsequent autoimmune response leading to chronic myocardial injury. Cases with high 
level of IL-10 during acute phase may be not likely to develop to chronic myocarditis or 
cardiomyopathy. So far, almost studies with human myocarditis have been limited to a small 
number of patients. Further large number prospective studies are required to prove our idea.  
In our previous study, the association of BNP with outcome was examined, also. Its levels in 
plasma were significantly increased in fulminant cases than in non-fulminant cases. 
However, we could not confirm its prognostic utility. In such cases, BNP may simply reflect 
the existence of circulatory failure alone. 
 
 
Serum levels of IL-10 were significantly increased in non-survivors than in survivors with fulminant 
myocarditis. IL-10 levels were significantly increased in not only patients with mechanical circulatory 
assist device on admission but also in those with it post admission, a few days after admission than in 
those without it throughout clinical course. IL: interleukin; FMC: fulminant myocarditis. (Nishii M, et 
al. J Am Coll Cardiol. 2004;44:1292-1297) 
Fig. 1. Serum level of interleukin-10 in patients with acute myocarditis. 
2.2.4 Cardiomyopathies 
The HF is a major complication in cardiomyopathies such as dilated cardiomyopathy 
(DCM), hypertrophic cardiomyopathy (HCM), and restrictive cardiomyopathy (RCM). BNP 
must be a useful prognostic predictor for cardiomyopathies.  
2.2.4.1 Dilated cardiomyopathy 
Recently, we reported prognostic utility of BNP in clinically stable 83 outpatients with 
nonischemic DCM after decompensated HF (13). They were in a clinically stable status 
during at least 6 months after hospital discharge at relatively low BNP level, namely mean 
BNP level of about 200 pg/ml. This implied that pre-discharge BNP level may predict a 
post-discharge outcome in nonischemic DCM, as reported in general decompensated HF 
patients (12). Additionally, in this observation, the prognostic value of post-discharge BNP 
level was identified. Especially, among various predictors, levels at 6 months after hospital 
discharge showed the closest relation to the high risk of readmission for decompensated HF 
and mortality (Table 2). This association was explained by adverse cardiac remodeling. 
Persistently high levels of BNP during 6 months were related to poor improvement on 
cardiac remodeling (Figure 2). 
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 Below vs. above median values 
Variable 
median 
level 
HR 95% CI P value 
Univariate analysis     
 Age 56 1.1895 
0.7431-
1.9246 
0.47 
 Sex (Female)  1.0347 
0.5886-
2.0433 
0.89 
 Hypertension  1.4902 
0.8912-
2.2819 
0.18 
 Atrial fibrillation  1.2965 
0.8885-
2.0973 
0.301 
 Ventricular tachycardia  1.2026 
0.6132-
2.1693 
0.57 
 Beta-blocker use  1.6691 
0.9056-
2.5641 
0.06 
 Diuretic use  1.3551 
0.8086-
2.1936 
0.24 
 Echocardiographic parameters     
  Left ventricular end-diastolic dimension at discharge 6.4 cm 0.8356 
0.5189-
1.3516 
0.48 
  Left ventricular ejection fraction at discharge 30% 1.1629 
0.7189-
1.8729 
0.54 
  Left atrial diastolic dimension at discharge 4.5 cm 1.3054 
0.8106-
2.1164 
0.28 
  Left ventricular end-diastolic dimension at 6 months 6.0 cm 1.3866 
0.8383-
2.3598 
0.22 
  Left ventricular ejection fraction at 6 months 36% 1.5019 
0.9209-
2.4641 
0.11 
  Left atrial diastolic dimension at 6 months 4.25 cm 2.0003 
1.2436-
3.2233 
0.0046 
 BNP measurements     
  Plasma BNP level at discharge 180 pg/ml 1.2642 
0.8051-
1.9888 
0.31 
  Plasma BNP level at 3 months 134 pg/ml 1.5097 
0.9413-
2.4212 
0.09 
  Plasma BNP level at 6 months 174 pg/ml 2.2679 
1.4336-
3.5863 
0.0005 
  Percentage change in BNP level between discharge and 3 
months 
-20.5% 1.4204 
0.8863-
2.2765 
0.14 
  Percentage change in BNP level between discharge and 6 
months 
-11.5% 2.0127 
1.2729-
3.1757 
0.0026 
Multivariate analysis     
  Plasma BNP level at 6 months 174 pg/ml 1.8427 
1.1127-
3.0426 
0.0181 
  Percentage change in BNP level between discharge and 6 
months 
-11.5% 1.6538 
0.9991-
2.7214 
0.051 
  Left atrial diastolic dimension at 6 months 4.25 cm 1.5678 
0.9486-
2.5904 
0.0792 
NYHA: New York Heart Association functional class; HR: hazard ratio; CI: confidence interval; BNP: B-
type natriuretic peptide (Nishii M, et al. J Am Coll Cardiol. 2008;51:2329-2335) 
Table 2. Univariate and multivariate Cox analyses of the incidence of death or readmission 
for heart failure.  
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2.2.4.2 Hypertrophic cardiomyopathy  
Several reports have demonstrated that BNP levels reflect the severity of symptoms and HF 
in HCM (28-29). Additionally, high level of BNP has been related to cardiac events including 
silent myocardial ischemia (30), admission for HF, and mortality (31). On the other hand, 
our previous observation was unable to confirm these values, because even patients with 
high levels of BNP were in a clinically stable status. In HCM, BNP expression, however, is 
thought to occur as a response to not only hemodynamic changes resulting from diastolic 
dysfunction and obstruction but also histological changes such as myocardial fiber disarray, 
hypertrophy of myocytes, and fibrosis (32). Thus, even in clinically stable patients with 
HCM, extremely high levels may indicate a poor long-term outcome. Further studies are 
required to elucidate its prognostic value in HCM. 
2.2.4.3 Restrictive cardiomyopathy  
There is no report regarding prognostic value of BNP in RCM. However, when RCM had a 
further increase of LV end-diastolic pressure (LVEDP) or systolic dysfunction, BNP level 
would be more increased (7). BNP measurement may predict the occurrence of 
decompensated HF, although its value remains uncertain in RCM. 
2.3 BNP-guided therapy  
Efficiency of BNP-guided therapy on cardiomyopathies is not yet elucidated. However, BNP 
levels reflect therapeutic effect in patients with HF. Aggressive treatment with diuretics and 
vasodilators such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II 
receptor antagonists reduce BNP level rapidly in conjunction with reduced intra-ventricular 
filling pressures. On the other hand, the effects of beta blockers on BNP concentrations are 
complex. Because adrenergic stimulation inhibits release of natriuretic peptides, beta 
blocking may initially increase BNP concentrations. By contrast, long-term use of beta 
blocker reduces BNP concentrations with the improvement in cardiac dysfunction. Thus, 
BNP measurement would help physicians to make clinical decisions to titrate 
pharmacological treatments. 
BNP-guided therapy improves a treatment outcome in patients with HF. Two 
provocative pilot studies have prospectively assessed the utility of BNP to guide 
selection and intensity of pharmacotherapy. In one study, 69 symptomatic patients 
(NYHA class II to IV) with impaired systolic function defined as LVEF of <40% were 
randomly allocated to receive either standardised clinical assessment consist of 
symptoms and physical findings-guided therapy or N-terminal BNP-guided therapy (< 
200 pmol/L) (33). During the follow up of at least 6 months, fewer patients had 
combined cardiovascular events (death, hospital admission, or heart failure 
decompensation) in the N-terminal BNP group than in the clinical group, which was 
associated with higher doses of ACEIs and diuretics. In a second multicenter randomised 
trial: The STARS-BNP Multicenter Study, 220 patients with symptomatic (NYHA class II 
to III) systolic HF defined as LVEF of <45% were randomized to medical treatments on 
either the basis of clinical findings from the physical examination and usual paraclinical 
and biological parameters or the basis of a decreasing BNP plasma levels of <100 pg/ml 
(34). After a mean follow-up of 15 months, significantly fewer patients had HF-related 
death in the BNP group than in the clinical group, which was in part associated with an 
increase in ACEIs and beta-blocker dosages.  
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Fig. 2. Changes in B-type natriuretic peptide (BNP) levels and echocardiographic findings 
during a clinically compensated status in patients with dilated cardiomyopathy (Nishii M, et 
al. J Am Coll Cardiol. 2008;51:2329-2335) 
Changes in BNP level at 3-month intervals after hospital discharge for decompensated heart 
failure (A) and in echocardiographic variables between discharge and 6 months (B). BNP 
levels were decreased during 6 months in event-free patients but not in readmitted patients, 
which was accompanied by the reduction of cardiac dimensions. Solid or open circles 
indicate BNP levels, echocardiographic dimensions (left ventricular end-diastolic dimension 
[LVDd]; left atrial diastolic dimension [LADd]), and left ventricular ejection fraction (LVEF) 
in event-free patients or patients readmitted for decompensated heart failure, respectively. 
Values are mean ± standard error of the mean. p values comparing changes in BNP and 
echocardiographic variables between readmitted patients and event-free patients are for 
repeated measures multivariate analysis of variance over 6 months. 
On the other hand, it remained uncertain whether BNP guide is available for asymptomatic 
patients or not. We reported that in 83 outpatients with asymptomatic (NYHA class I to II) 
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systolic HF defined as LVEF of <40%, BNP cutoff point of about 200 pg/ml at 6 months after 
the discharge for decompensated HF can identify patients at the high risk of readmission 
and sudden death (13) (Figure 3). Interestingly, Beta blocker use and its dosage were 
significantly lower in high risk patients [>200 vs. <200 pg/ml: 60 vs. 100%, P=0.001; 8 ± 5 vs. 
16 ± 5 mg/day (carvedilol), P=0.0003; 64 ± 22 vs. 107 ± 40 mg/day (metoprolol), P=0.036; 
respectively]. The cutoff point might determine the requirement of initiation or titration of 
beta blockers. Even in asymptomatic HF setting, BNP-guided therapy may be also helpful.  
2.4 The limitations on BNP-guided therapy  
We have to consider the limitations on BNP-guided therapy, also. Recent multicenter trial (the 
randomized Trial of Intensified vs. Standard Medical Therapy in Elderly Patients with 
Congestive Heart Failure: TIME-CHF) could not identify the advantage of BNP-guided 
therapy over symptom-guided therapy in 499 elderly patients aged more than 60 years with 
symptomatic (NYHA class II or greater) systolic HF (LVEF of <45%) and prior hospitalization 
for decompensated HF (35). They were randomized to N-terminal BNP-guided HF therapy 
(levels of less than two times the upper limit of normal) and symptom-guided HF therapy 
(NYHA class of less than II). However, the improvements of outcomes including mortality, 
hospitalization, and quality of life were similar in both groups. Especially in patients aged 
more than 75 years, BNP-guided HF therapy did not improve outcome. In general, dosages of 
drugs such as ACEIs and beta-blockers are increased more in patients receiving BNP–guided 
therapy. Although persistence in intensifying medical therapy seems to be indispensable for 
better outcome in young and middle aged patients, it may be harmful to push dosages to the 
limits in elderly patients aged more than 75 years. Additionally, BNP-guided therapy may be 
disadvantageous in patients with low output syndrome resulting from severe systolic and 
diastolic dysfunctions. Because such cases require more ventricular load as a compensatory 
mechanism for congestive HF, rapid titration of ACEIs, beta blockers, and diuretics on the 
basis of BNP-guided HF therapy may lead to further deterioration of HF. Furthermore, 
edtablished cardiomyopathy with irreversible LV dilatation often shows persistently high 
level of BNP despite aggressive treatment for HF. A unified level of BNP-guided therapy 
would be unavailable for such cases. These emphasize the need of setting up individual BNP 
target level in accordance with cardiac conditions. 
2.5 Individual target threshold of BNP  
To set up individual target threshold of BNP for the risk reduction that were associated with 
cardiac dilatation and identify its prognostic utility, clinically stable 113 patients with systolic 
HF after decompensated HF represented by non-ischemic dilated cardiomyopathy were 
examined. Among these patients, 32 patients reached end-point composed of readmission for 
decompensated HF or death. Various variables were related to its combined event, including 
atrial fibrillation, low LVEF below the best cutoff value of 34%, cardiac dilatation (CD) 
indicated by left ventricular end-diastolic dimension×LAD/wall thickness/body surface area 
above the best cutoff value of 115 /m2, high levels of BNP above the best cutoff value of 195 
pg/ml.  Furthermore, we found a significant positive correlation between BNP level and CD 
specific for event-free patients. The rage between 95% confidence interval on this specific 
linear regression line were closely associated with an incidence rate of readmission or death, 
also (Figure 4A, B). Thus, we defined this rage as individual target threshold of BNP.  
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Fig. 3. Kaplan-Meier Analyses  (Nishii M, et al. J Am Coll Cardiol. 2008;51:2329-2335) 
Kaplan-Meier curves showing the incidence rate of readmission for decompensated heart 
failure or sudden death (A) or of readmission alone (B) according to 6-month post-discharge 
B-type natriuretic peptide (BNP) ranges in outpatients with dilated cardiomyopathy.   
The risk of a combined event increased in a stepwise fashion across increasing ranges of 6-
month post-discharge BNP, namely at <190 pg/ml, 190 to 380 pg/ml, and >380 pg/ml (Fig. 
2A). Further, Kaplan-Meier curves for incidence of readmission alone (Fig. 2B) showed the 
same pattern. B-type natriuretic peptide ranges were <190 (the best cutoff level for 
predicting readmission or sudden death), 190 to 380, and >380 (its 2-fold level) pg/ml. p < 
0.0001 (the log-rank test) versus a BNP range of <190 pg/ml. 
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Next, we examined its prognostic advantage over other variables. When adjusted to high-risk 
patients with advanced dilated cardiomyopathy, namely symptomatic non-ischemic systolic 
HF (LVEF below 34%) complicated by severe cardiac dilatation (CD above 115 /m2), this 
individual target threshold alone was associated with the incidence rate (Figure 5). Based on 
Laplace Law (pressure x radius/2 wall thickness), this threshold may reflect individual 
optimal wall stretch for clinical stabilization. The left atrium (LA) acts as a reservoir during LV 
overload (36), and elevated LV filling pressure results in LA overload as well as LV diastolic 
dysfunction (37). Thus, LA dimension reflects intra-ventricular pressure, in part.   
A combined assessment of BNP level and echocardiographic dimensions may facilitate 
individual disease management. Among overall patients, those with BNP levels over or 
under its target threshold required titration or withdrawal, respectively of pharmocological 
therapy including diuretics or vosadilators to keep a balance between ventricular load and 
cardiac function. Additionally, cases refractory to such pharmacological optimization may 
be considered application of mechanical circulatory assist device implantation or 
subsequent surgical intervention including heart transplantation.  
 
 
Fig. 4. Prognostic utility of individual target threshold of B-type natriuretic peptide (BNP) 
on readmission for decompensated heart failure or sudden death in patients with non-
ischemic dilated cardiomyopathy 
A: Individual target threshold of BNP. Event-free patients had a significantly positive 
correlation between BNP level and cardiac dilatation (CD) (r=0.88; P<0.0001), but event 
patients did not (r=0.26; P=0.421). BNP levels in event patients tended to be out of the range 
between dotted lines: 95% confidence interval (CI) on solid line: the linear regression line 
specific for event-free patients (BNP= -144.64 + 3.16×CD), namely individual target 
threshold of BNP. B: Kaplan-Meier curves showing the incidence rate of event according to 
individual target threshold of BNP. Out of this threshold was closely associated with an 
increase in event risk (the log-rank test: P<0.0001).  
Open circles or triangles indicate even-free or event patients, respectively. CD was defined 
as left ventricular end-diastolic dimension×left atrial diastolic dimension/wall 
thickness/body surface area. 
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Fig. 5. Prognostic predictors on readmission for decompensated heart failure or death in 
patients with advanced dilated cardiomyopathy, namely symptomatic systolic heart failure 
(left ventricular ejection fraction below the best cutoff value of 34%) complicated by severe 
cardiac dilatation (CD) above the best cutoff value of 115 /m2. 
A: Kaplan-Meier curves showing the incidence rate of event according to levels of BNP 
above or below the best cutoff value of 340 pg/ml or atrial fibrillation. These variables had 
no significant association with an increase in event risk (the log-rank test; BNP levels: 
P=0.2689; atrial fibrillation: P=0.4450). B: Individual target threshold of BNP. Event-free 
patients had a significantly positive correlation between BNP level and CD (r=0.91; 
P<0.0001), independently of event patients (r=0.10; P=0.71). BNP levels in event patients 
tended to be out of individual target threshold of BNP between dotted lines: 95% confidence 
interval (CI) on solid line: the linear regression line specific for event-free patients C: 
Kaplan-Meier curves showing the incidence rate of event according to individual target 
threshold of BNP. Out of individual target threshold of BNP was significantly associated 
with an increase in event incidence (the log-rank test: P<0.0001).  
Open circles or triangles indicate even-free or event patients. CD was defined as left 
ventricular end-diastolic dimension×left atrial diastolic dimension/wall thickness/body 
surface area. 
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The number of patients in our study is, however, relatively small, and our population was 
limited to only patients with non-ischemic dilated cardiomyopathy. Additional prospective 
multi-center studies including cases with ischemic heart disease would confirm our 
observation and extend it to various settings of systolic HF.  
3. Conclusion  
BNP measurement has facilitated the diagnosis of HF and decision of pharmacotherapy 
and improved outcome during the hospitalization and after the discharge for 
decompensated HF in cardiomyopathies, although BNP cutoff points for risk assessment 
are different on time course after decompensated HF and cardiac dysfunctions. On the 
other hand, availability of this BNP measurement was less especially in patients with 
advanced dilated cardiomyopathy as well as in elderly patients. However, individual 
target threshold of BNP for risk reduction related to cardiac dilatation exerted a strong 
prognostic power even in such advanced cases. This target threshold-guided therapy 
would facilitate individual disease management and thus contribute to further 
improvement of treatment outcome. 
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